<DOC>
	<DOCNO>NCT00190944</DOCNO>
	<brief_summary>Effects Teriparatide Distal Radius Fracture Healing</brief_summary>
	<brief_title>Effects Teriparatide Distal Radius Fracture Healing</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Radius Fractures</mesh_term>
	<mesh_term>Colles ' Fracture</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Ambulatory , postmenopausal , woman 45 85 year age . Postmenopausal define least 2 year without regular menses Sustained unilateral , dorsally angulated fracture distal radius within 10 day Received conservative treatment distal radius fracture , include closed reduction immobilization device ( cast , splint , brace ) Free severe chronically disable condition distal radius fracture determine investigator Without language barrier , cooperative , expect return followup procedure , give informed consent enter study inform risk , medication procedure use study . In opinion investigator , patient willing train use peninjector daily , able satisfactorily use pentype injection delivery system , willing receive daily subcutaneous injection care partner train use pen injector Increased baseline risk osteosarcoma History malignant neoplasm 5 year prior visit 2 , exception superficial basal cell carcinoma squamous cell carcinoma skin definitely treat Have currently know , suspect , history disease affect bone metabolism postmenopausal osteoporosis cause secondary osteoporosis clinically active 1 year prior visit 2 Have elevate serum calcium value Active liver disease clinical jaundice History symptomatic nephroor urolithiasis 2 year prior visit 2 Previous fracture bone surgery currently fracture distal forearm Joint disease rheumatoid arthritis disable osteoarthritis clearly affect function wrist and/or hand injure arm Requirement chronic treatment nonsteroidal antiinflammatory drug define 3 consecutive month NSAID treatment Treatment : Oral bisphosphonates 18 month prior 3 year , receive oral intravenous biphosphonate therapy within last 2 month prior screen . Oral strontium ranelate duration Systemic corticosteroids 30 day ( total ) 6 month prior visit 2 , systemic corticosteroid dose 1 month prior visit 2 . Ophthalmic , oric , topical , nasally inhale corticosteroid therapy may use without restriction . Fluoride therapeutic dos ( great equal 20mg/day ) 3 month last 2 year total 2 year , dosage within 6 month prior visit 2 .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>